PharmacoEconomics invites the submission of papers (original research, reviews and opinion pieces) on improving transparency in decision models for a themed issue of the journal to be published in 2019 and guest edited by Paul Tappenden (University of Sheffield) and Jaime Caro (London School of Economics and McGill University). We encourage papers from the perspectives of a variety of stakeholders including methodologists, payers, health technology assessment bodies, analysts, pharmaceutical industry, advocacy groups and software developers. Country-specific perspectives are also encouraged. Papers can be either methodological or applied. Continue reading “Call for Papers: Themed Issue – Improving Transparency in Decision Models”
Chris Carswell, Co-Editor in Chief, PharmacoEconomics
I am not a frequent blogger but one recurring issue has forced me to put finger to keyboard – insufficient detail and transparency in many submitted cost effectiveness analyses. Reporting checklists have been available for many years. According to Web of Science, the 1996 Drummond checklist has been cited over 950 times. CHEERS, published in 2013, has been cited over 260 times and is one of the most downloaded Task Force Reports from the International Society of Pharmacoeconomics and Outcomes Research. In addition, authors continue to identify the need for reporting improvement to aid transparency and facilitate model replication. So, why the apparent lack of compliance with well-recognized reporting checklists? Continue reading “Reporting Cost Effectiveness Analyses: Time for Improvement”
PharmacoEconomics invites the submission of manuscripts with a focus on family spillover effects of illness for a special issue of the journal to be published in 2018.
The issue will focus on methods and applications for measuring spillover effects as well as conceptual papers discussing methodological and practical issues.
In a paper previously published in PharmacoEconomics, Guest Editors Eve Wittenberg and Lisa Prosser state:
Caring for an ill or disabled family member imposes a well-documented burden on the caregiver. The benefits of a health intervention may be underestimated if “spillover” effects on family members are not captured, resulting in inaccurate conclusions of economic evaluations.
For the context of this special issue, family spillover is defined as the effect on an individuals’ quality of life due to having a family member with a chronic illness. We consider spillover to include family caregivers as well as non-caregivers. Extensions to larger social networks may also be included with justification (e.g., classmates for children’s illnesses).
Topics of interest include:
- Applications: Measurement of spillover for specific conditions or populations of interest, inclusion of spillover in cost-effectiveness analyses.
- Methods: Conceptual frameworks, measurement tools or approaches, methodological or practical issues in measurement; challenges to application in CEA.
Please submit an abstract describing your proposed paper by July 31, 2017 to the Editor, Chris Carswell . Full papers will be invited by August 31, 2017 and manuscripts due in early 2018.